NASDAQ · GH
Guardant Health, Inc.
$185.31+$2.72 (+1.49%)
Guardant Health, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.0% below the high.
Loading market information…
NASDAQ · NEO · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
NeoGenomics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.02% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
NeoGenomics, Inc.’s next earnings report is currently expected on Feb 16, 2027, with estimated earnings per share of $0.06. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow NeoGenomics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists, clinicians, pharmaceutical companies, and researchers. NeoGenomics' advanced testing capabilities encompass cytogenetics, which examines normal and abnormal chromosomes in relation to disease; fluorescence in-situ hybridization (FISH) for detecting and pinpointing specific DNA sequences and genes on chromosomes; and flow cytometry, used to measure cell population characteristics. Additionally, the company provides immunohistochemistry and digital imaging services, enabling the localization of cellular proteins in tissue sections, visualization of scanned slides, and quantitative analysis. Molecular testing, focusing on DNA/RNA analysis and gene structure/function, is also a key offering, alongside morphologic analysis where pathologists microscopically diagnose cells. Beyond clinical diagnostics, NeoGenomics supports pharmaceutical clients' oncology programs from discovery to commercialization and acts as a reference laboratory for anatomic pathology testing. The company, founded in 2001 and headquartered in Fort Myers, Florida, also maintains a strategic alliance and laboratory services agreement with Inivata Limited.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:23 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2025 | Jul 29, 2025 | $0.030.0% vs estimate | $181.33M-1.37% vs estimate |
|---|
| Q1 2025 | Apr 29, 2025 | -$0.08-300.0% vs estimate | $168.04M-8.14% vs estimate |
|---|
| Q4 2024 | Feb 18, 2025 | $0.04+33.33% vs estimate | $172.00M-0.34% vs estimate |
|---|
THE ANALYST VIEW
30 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 4 contributors · Median target $21.50.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$185.31+$2.72 (+1.49%)
Guardant Health, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.0% below the high.
$158.92+$1.04 (+0.66%)
GRAIL Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.54% below the high.
$52.17+$1.86 (+3.7%)
Veracyte, Inc.’s quoted price sits in the upper half of its reported 52-week range, 14.35% below the high.
$71.02+$6.33 (+9.79%)
GeneDx Holdings Corp.’s quoted price sits in the lower half of its reported 52-week range, 58.44% below the high.
$15.93-$0.08 (-0.47%)
Personalis, Inc.’s quoted price sits in the upper half of its reported 52-week range, 15.7% below the high.
$38.51+$1.83 (+4.99%)
Castle Biosciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 13.03% below the high.
$6.67+$0.04 (+0.6%)
Myriad Genetics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 20.41% below the high.
$8.70+$0.30 (+3.57%)
Exagen Inc.’s quoted price sits in the upper half of its reported 52-week range, 27.01% below the high.
